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Effective therapeutic vaccines often require activation 
of T cell-mediated immunity. Robust T cell activation, 
including CD8 T cell responses, can be achieved using 
antibodies or antibody fragments to direct antigens of 
interest to professional antigen presenting cells. This 
approach represents an important advance in enhancing 
vaccine efficacy. Nucleic acid aptamers present a promis-
ing alternative to protein-based targeting approaches. 
We have selected aptamers that specifically bind the 
murine receptor, DEC205, a C-type lectin expressed 
predominantly on the surface of CD8α+ dendritic cells 
(DCs) that has been shown to be efficient at facilitating 
antigen crosspresentation and subsequent CD8+ T cell 
activation. Using a minimized aptamer conjugated to 
the model antigen ovalbumin (OVA), DEC205-targeted 
antigen crosspresentation was verified in vitro and in vivo 
by proliferation and cytokine production by primary 
murine CD8+ T cells expressing a T cell receptor spe-
cific for the major histocompatibility complex (MHC) 
I-restricted OVA257–264 peptide SIINFEKL. Compared with 
a nonspecific ribonucleic acid (RNA) of similar length, 
DEC205 aptamer-OVA-mediated antigen delivery stimu-
lated strong proliferation and production of interferon 
(IFN)-γ and interleukin (IL)-2. The immune responses 
elicited by aptamer-OVA conjugates were sufficient to 
inhibit the growth of established OVA-expressing B16 
tumor cells. Our results demonstrate a new application 
of aptamer technology for the development of effective 
T cell-mediated vaccines.
Received 10 December 2013; accepted 19 March 2014; advance online  
publication 6 May 2014. doi:10.1038/mt.2014.51
INTRODUCTION
Poor immunogenicity of conventional protein vaccines, in par-
ticular an inability to elicit robust T cell-mediated immunity, has 
limited their use as vaccines targeting diverse diseases including 
viral infections and cancers. One approach, which has recently 
been utilized to activate T cell responses, is targeting of antigen 
to dendritic cells (DCs), a cell type that is pivotal for eliciting 
T cell activation. Indeed, DC-targeted approaches have recently 
attracted significant research interest and are rapidly becoming 
important therapeutic approaches.1–4 DCs possess the capability 
of processing self and foreign antigens resulting in presentation 
of antigen to its cognate T cell receptor. Targeting antigen uptake 
to DCs via specific DC-enriched receptors has been shown to 
enhance antigen presentation on major histocompatibility com-
plex (MHC) class I and II molecules by as much as 1,000-fold and 
50-fold, respectively.5 Depending on the antigenic stimulus, DCs 
can induce tolerance or activate the immune system,6 making 
them important targets in the development of novel therapies for 
treating autoimmune diseases, viral infections, and cancer.
Targeting antigens to DCs most often involves coupling the 
antigen of interest to a delivery agent specific for a readily endo-
cytosed cell surface receptor. Typically, targeted antigen delivery 
has made use of antibodies as the targeting agent. Nucleic acid 
aptamers, however, due to their unique chemical properties and 
low immunogenicity, provide a promising alternative to anti-
body-based antigen delivery.7,8 Aptamers are short ribonucleic 
acid (RNA) or deoxyribonucleic acid (DNA) sequences gener-
ated in vitro by an iterative selection process (systematic evolu-
tion of ligands by exponential enrichment (SELEX)) to bind 
with high affinity and specificity to a given target. Aptamers have 
demonstrated a wide range of flexibility, finding applications in 
flow cytometry staining, activating signaling pathways through 
cell surface receptor ligation, drug or siRNA delivery, blocking 
protein-protein interactions, and inhibiting enzyme function.7–9 
Several aptamer-based therapeutics are currently undergoing 
clinical trials, with one already approved for clinical use.10
With the goal of utilizing aptamers for targeted antigen deliv-
ery, we have identified aptamers that recognize the murine recep-
tor DEC205 (mDEC205) and have subsequently adapted them 
for use as a targeted antigen delivery agent. DEC205 is an excel-
lent target receptor for this proof-of-principle study. This C-type 
lectin is expressed mainly by CD8α+ DCs, with lower expression 
by other cells in the hematopoietic lineage (> 1 log less).11 More 
importantly, studies targeting this receptor with anti-DEC205 
antibodies fused to a variety of different antigens have demon-
strated that receptor targeting leads to efficient crosspresentation 
of these molecular cargoes including cancer12,13 and HIV epit-
opes.14,15 Indeed, a cancer vaccine utilizing anti-human DEC205 
antibody is already being tested in the clinic.16
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A sequential selection strategy of recombinant mDEC205 
protein followed by cells expressing mDEC205 was used to 
identify nuclease-stabilized RNA aptamers specific for the 
mDEC205 receptor. Minimized aptamers conjugated to the 
model chicken antigen ovalbumin (OVA) specifically bound 
mDEC205-expressing cell lines and primary cells. In the pres-
ence of the adjuvant polyinosinic:polycytidylic acid (pIC), incu-
bation of anti-DEC205 aptamer:OVA conjugates with primary 
DCs in vitro resulted in crosspresentation of antigen, as deter-
mined by T cell proliferation assays and cytokine secretion. 
Fluorescently labeled aptamer localized to DEC205+CD11c+ 
cells in the spleen following systemic injection but only when 
displayed multivalently. Administration of multivalent, but not 
monovalent aptamer:OVA conjugates together with the adjuvant 
pIC resulted in T cell activation in vivo, as determined by pro-
liferation and production of interferon (IFN)-γ and interleukin 
(IL)-2 by OVA-specific OT-I cells. Using a flank B16-OVA mela-
noma model, we found that only injection of multivalent DEC205 
aptamer:OVA conjugates, not a multivalent nontargeting con-
trol aptamer:OVA conjugate, was able to elicit crosspresentation 
that was sufficient to cause regression of established B16-OVA 
tumors. Our results bode well for the future development of 
aptamer-based vaccines for eliciting immunological responses 
for the development of immune-targeted therapies such as anti-
viral and cancer vaccines.
RESULTS
Identification of anti-mDEC205 aptamers
Pool enrichment. In order to identify aptamers that specifi-
cally recognized mDEC205 and were readily internalized by 
cells that naturally express this receptor, we employed a three-
stage selection procedure (Figure 1a). Starting with an initial 
2′-fluoro-pyrimidine-modified (2′F) RNA library encompassing 
~1014 unique sequences, we performed three rounds of selection 
utilizing a recombinant mDEC205-hIgGFC fusion protein pro-
duced in Chinese hamster ovary (CHO) cells. Surprisingly, when 
we assayed each round of the selection against CHO-mDEC205 
cells (a CHO cell line engineered to overexpress mDEC205) by 
flow cytometry, the Round 3 population already showed marked 
staining (Figure 1b; CHO-mDEC205). Importantly, no apparent 
Figure 1 Selection, cloning, and characterization of anti-mDEC205 aptamers. (a) Selection scheme. Three rounds of selection were performed 
against recombinant mDEC205-hIgG1FC fusion protein, with negative selection against hIgG1FC included in Rounds 2 and 3. Round 4 was performed 
against the surface of Chinese hamster ovary (CHO)/mDEC205, while Round 5 selected for sequences internalized by mouse bone marrow–derived 
dendritic cells (BMDCs). See Materials and Methods for full procedure. (b) Binding of selection rounds to surface-expressed mDEC205. Individual 
selection rounds were hybridized with a biotinylated oligonucleotide complementary to a portion of the aptamer pool’s 3′ constant region, incubated 
with CHO/mDEC205 or CHO cells, counter-stained with SA-PE, and analyzed by flow cytometry. (c) Predicted secondary structure of minimized anti-
mDEC205 aptamer, min.2. The conserved seven-base motif appearing in most clones—“UUCAUAA”—is highlighted in red. (d) Apparent binding 
constant for min.2 against mDEC205+ A20.Kb cells as determined by flow cytometry. Kd app = 23 ± 6 nmol/l. (e) Binding of minimized, Dy649-labeled 
anti-mDEC205 aptamer min.2 to primary mDEC205+ BMDCs. The identity of each histogram is as indicated in the key adjacent to the plot.
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staining was observed when the assay was repeated with the pa-
rental CHO cells (Figure 1b; CHO).
In order to further enrich the population for aptamers that 
bound to the receptor in the context of the cell surface, for Round 
4, we switched to a cell-based selection utilizing CHO-mDEC205 
cells. Prior to the selection, we performed a negative selection 
step on CHO cells to deplete the population of any nonspecific 
cell binders. Following positive selection on CHO-mDEC205 
cells, bound RNA was recovered amplified and assayed by flow 
cytometry.
The Round 4 RNA showed no improvement in binding and 
uptake of the aptamer over Round 3 (Figure 1b), which prompted 
us to turn an additional round with further modification to our 
selection scheme. For this, we targeted bone marrow–derived DCs 
(BMDCs), a model for “classical” CD11c+ DCs, which express 
mDEC205 and are capable of antigen crosspresentation.17,18 Our 
goal was to ensure that our selected aptamers could bind their tar-
get receptor and be efficiently internalized. Therefore, following 
a 1-hour incubation with the aptamer library in media, the cells 
were stringently washed with buffer followed by acidic glycine to 
remove surface-bound molecules. Finally, the cells were trypsin-
ized and then treated with an RNAse cocktail to ensure that only 
RNAs that had been internalized by the cells were recovered. As 
shown in Figure 1b, when assayed on CHO/mDEC205 cells, the 
Figure 2 Min.2, but not cntrl.36, binds to and is internalized by DEC205+ cells. Confocal microscopy images of Chinese hamster ovary (CHO)-
mDEC205 cells (a, c, d) or primary mDEC205+ bone marrow–derived dendritic cells (BMDCs) (b) following incubation with fluorescently labeled 
min.2 or cntrl.36. (a, b) Cells were incubated with 200 nmol/l Dy649-labeled min.2 or cntrl.36 (red) and incubated for 1 hour at 37 °C to allow 
endocytosis, at which time the cells were stringently washed and the cell surface was stained with (a) DEC205 or (b) CD11c antibodies labeled with 
AF488 (green). Panel labeled “min.2” (inset) is a magnification of the white boxed region in (b). (c) Colocalization of AF488-labeled min.2 (green) 
and AF647 labeled anti-DEC205 antibody (clone 205yekta; red)). Colocalization of AF488-labeled min.2 (top) or AF488-labeled anti-DEC205 anti-
body (bottom) with (d) RFP-labeled Rab5a (early endosome), or (e) RFP-labeled LAMP-1 (lysosome). (f–i) Binding and uptake of large (~300 kDa) 
molecule cargoes by BMDCs. Flow cytometry was used to assess binding and internalization of aptamer-SA:PE conjugates. Biotinylated min.2 or 
cntrl.36 were precomplexed with SA:PE and subsequently incubated with BMDCs at the indicated temperatures. Following a 1-hour incubation, cells 
were washed and then treated with an RNAse cocktail as indicated.
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Round 5 population showed improvement in aptamer binding 
and uptake over Round 4.
Clone analysis and minimization. Flow cytometric analysis of 
individual clones identified from Round 5 population revealed that 
nearly all isolated clones bound CHO-mDEC205, but not CHO 
cells (Supplementary Figure S1). Sequence analysis revealed a 
seven base sequence (5′-UUCAUAA-3′) that recurred in several 
clones (Figure 1c and Supplementary Figure S1b) that often 
formed a short loop when the constructs were folded. Interestingly, 
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two clones that showed some of the best activity (Clones 1 and 15) 
possessed identical random regions, with the only difference be-
ing that the Clone 1 sequence lacked a significant portion of the 
3′ constant region present in Clone 15 and the rest of the library. 
Using these clones as a starting point, we tested a series of succes-
sive truncations aimed at preserving this sequence but minimizing 
the overall size of the aptamer. This resulted in the identification 
of a minimized sequence composed of a 42- nucleotide aptamer 
core, “min.2” which performed better than the bulk Round 5 pool 
(Figure 1c and Supplementary Figure S2).
The minimized aptamer, min.2, was chemically synthesized bear-
ing a 3′ inverted dT for added serum stability and a 5′ thiol to facili-
tate subsequent chemical conjugations. Using biotin maleimide, we 
generated biotinylated minimized aptamers and verified the speci-
ficity of this construct for mDEC205 using siRNA to knock down the 
expression of mDEC205 on CHO/mDEC205 cells by flow cytom-
etry using streptavidin (SA)-phycoerythrin (PE) (Supplementary 
Figure S3). Specificity for DEC205 was further confirmed using A20.
Kb cells, a B cell lymphoma line that naturally expresses mDEC205, 
as well as A20.Kb-mDEC205 cells, a variant of A20.Kb cells engi-
neered to express higher levels of mDEC205 (Supplementary 
Figure S4). Using an Alexa Fluor 488-maleimde conjugate of 
min.2, we measured the apparent dissociation constant of this 
aptamer for cell-surface mDEC205 on A20.Kb cells (23 ± 6 nmol/l; 
Figure 1d). Consistent with these results, when we incubated a 
Dy649-labeled minimized aptamer with CD11c+ BMDCs, signifi-
cant cell staining was observed (Figure 1e; red). Importantly, a non-
targeting control aptamer showed minimal staining under these 
same conditions (Figure 1e; green).
Using this minimized construct, we performed micros-
copy studies to confirm that receptor binding was accompanied 
by internalization. Experiments performed using both CHO-
DEC205 cells (Figure 2a) as well as CD11c+ BMDCs (Figure 2b) 
displayed punctate staining following incubation with the 
labeled aptamer, but not a nonfunctional sequence of similar size 
(cntrl.36). To further confirm specificity, we performed colocal-
ization studies using CHO-DEC205 cells. When coincubated 
with cells, both min.2 and an anti-DEC205 antibody colocalized 
to the same intracellular compartments (Figure 2c). Consistent 
with published studies, the DEC205 antibody showed minimal 
colocalization with early endosomes and more extensive localiza-
tion with lysosomes,19,20 with min.2 exhibiting similar intracellular 
localization (Figure 2d,e).
Because antigen delivery requires uptake of cargoes signifi-
cantly larger than small molecule fluorophores, we generated 
aptamer-PE conjugates (a ~3 kDa protein) using a biotinylated 
aptamer and SA-PE and assessed binding and cellular uptake of 
these large cargoes by BMDCs. The min.2-PE conjugate showed 
significant staining when incubated with CD11c+ BMDCs at 4 °C, 
which was reduced to near-background levels when treated with 
an RNAse cocktail which destroys even 2′F RNA (Figure 2f).21 
However, when the same experiment was performed at 37 °C, the 
bulk of the fluorescence signal remained intact (Figure 2g) indi-
cating that the aptamer and cargo had been internalized and thus 
protected from digestion. Similar experiments conducted using a 
nontargeting aptamer control yielded only background fluores-
cence when cells were incubated at 4 °C (Figure 2h), with slightly 
higher background levels observed at 37 °C (Figure 2i). Taken as 
a whole, these data further demonstrate the functionality of min.2 
for binding DEC205 and enabling internalization of large molecu-
lar cargoes into target cells.
Enhancing crosspresentation with anti-mDEC205 
aptamers
Aptamer-OVA conjugation. Antibodies that target DEC205 
have been shown to greatly enhance the crosspresentation of an-
tigens.5,6,22 To this end, we chose to utilize the well-characterized 
OVA system as a model to investigate the ability of min.2 to de-
liver cargo for crosspresentation.
Using the 5′-thiol-modified min.2, we generated aptamer-
OVA conjugates using the heterobifunctional crosslinker 
N-[γ-maleimidobutyryloxy]sulfosuccinimide ester (sulfo-GMBS; 
Supplementary Figure S5). As a control to ensure specificity, 
we also generated OVA conjugates using a nonfunctional con-
trol sequence, cntrl.36. Conjugates were subsequently purified by 
anion exchange high-performance liquid chromatography with 
the protein conjugate eluting in two distinct peaks (Fraction #1; 1:1 
aptamer:OVA and Fraction #2; 2:1 aptamer:OVA; Supplementary 
Figure S5). Subsequent experiments were performed using the 
first fraction, which consisted of a single aptamer conjugated to 
OVA, as determined by the ratio of the UV absorbance at 260 
and 280 nm. Finally, to ensure that the aptamer-protein conju-
gates remained functional, we generated fluorescently labeled 
conjugates and confirmed binding to CHO/mDEC205 cells 
(Supplementary Figure S5).
Min.2-OVA is functional for crosspresentation. We initially as-
sessed the ability of our anti-mDEC205 aptamer (min.2) to enhance 
delivery and crosspresentation of protein antigens in vitro using mu-
rine CD11c+ splenocytes, a subset of which are CD8α+DEC205+.22 
Figure 3 Min.2 is functional for crosspresentation in vitro. (a) Proliferation of carboxyfluorescein succinimidyl ester (CFSE)-labeled OT-I cells 
 following incubation of monovalent aptamer:OVA conjugates or controls with primary dendritic cells (DCs). CD11c+ DCs were isolated from the 
spleens of C57BL/6 mice. After isolation, 4 × 105 DCs were incubated with pIC plus lipopolysaccharide for 4 hours (except Dulbecco's phosphate-
buffered saline labeled), followed by overnight incubation with 10 nmol/l conjugate or controls for 16–20 hours at 37 °C. The next day, a single-cell 
suspension of 1 × 105 CFSE-labeled OT-I cells was added, and the cells were incubated for an additional 3 days at 37 °C, washed with flow cytometry 
buffer, stained with 4′,6-diamidino-2-phenylindole and antibodies against CD8α and TCR-β, and analyzed by flow cytometry. See Materials and 
Methods for full procedure. (b–d) Intracellular cytokine staining of OT-I cells in (a). Cells were treated with 10 μg/ml brefeldin A, incubated for 5 
hours at 37 °C, stained with antibodies against CD25, interleukin (IL)-2, and interferon (IFN)-γ, and analyzed by flow cytometry. OT-I responses fol-
lowing incubation with min.2:OVA versus cntrl.36:OVA and NLDC145:OVA versus IgG2a:OVA were compared by student’s t-test (****P < 0.0001). 
Data shown are representative of three experiments. Secretion of cytokines (e) IFN-γ and (f) IL-2 into the media by cells following OT-I proliferation 
assays performed in the presence of 10 nmol/l aptamer:OVA or antibody:OVA conjugates, free OVA (OVA) or treatment with 100 nmol/l SIINFEKL 
peptide. (g) Dose–response analysis of cells to aptamer or control treatments. Proliferation of CFSE-labeled OT-I cells was monitored following incuba-
tion with primary DCs with a graded dose of aptamer (min.2 or cntrl.36) or antibody (rIgG2a or NLDC145; where rIgG2a is an isotype control) OVA 
conjugates. The concentration of conjugate used is indicated. OVA, ovalbumin.
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In short, purified DCs were incubated with the adjuvants lipopoly-
saccharide and/or pIC and either 10 nmol/l aptamer-OVA conju-
gate (min.2:OVA or cntrl.36:OVA) or 10 nmol/l antibody-OVA fu-
sion (NLDC145:OVA or GL117:OVA, a rat IgG2a anti-Escherichia 
coli β-galactosidase antibody which served as an isotype control) 
for 24 hours at which time the cells were washed and incubated with 
carboxyfluorescein succinimidyl ester (CFSE)-labeled OT-I cells. T 
cell activation was assessed 3 days later by flow cytometry. As shown 
in Figure 3a, targeting antigens with either the mDEC205-specific 
aptamer-OVA conjugate (min.2:OVA) or antibody-OVA chimera 
(NLDC145:OVA) induced a strong activation response, with most 
cells (>90%) dividing after 3 days, whereas incubations performed 
with the nonspecific RNA conjugate (cntrl.36:OVA) or isotype an-
tibody chimera (rIgG2a:OVA) resulted in minimal T cell division. 
Importantly, when cells were treated with aptamer alone (data not 
shown) or a combination of aptamer plus OVA (not conjugated; 
min.2 + OVA), the observed levels of proliferation were similar to 
that of the Dulbecco's phosphate-buffered saline (DPBS)-treated 
control (Figure 3a; DPBS). Consistent with the observed prolifera-
tion, only cells which received the min.2:OVA or NLDC145:OVA 
conjugates upregulated the surface activation marker, CD25 
(Figure 3b) and produced the cytokines IFN-γ (Figure 3c) and 
IL-2 (Figure 3d). Similar levels of activation were observed when 
cells were treated with min.2:OVA in the presence of pIC only, or 
following treatment with the SIINFEKL peptide (data not shown). 
When we assayed IL-2 and IFN-γ in the culture supernatant by 
enzyme-linked immunosorbent assay, the antibody-targeted and 
aptamer-targeted OVA displayed slightly different responses. 
Both treatments induced secretion of IFN-γ and IL-2 by OT-I 
cells at 24 and 48 hours (Figure 3e,f). However, incubation with 
min2:OVA resulted in approximately twofold greater level of IFN-γ 
at 24 hours and significantly lower amounts of IL-2 compared with 
NLDC145:OVA. When we performed similar experiments to de-
termine the dose response of min.2:OVA, we observed significant 
crosspresentation at concentrations down to 1 nmol/l (Figure 3g).
To ensure that our aptamers and aptamer-conjugates did not 
provoke any adverse effects on cells, we monitored DCs treated 
for 24 hours with our aptamer-OVA conjugates for upregula-
tion of the activation markers CD80, CD86, CD40, and MHC II. 
Importantly, DCs incubated with the aptamer or control conju-
gates in the absence of adjuvants were not activated when com-
pared with DCs given DBPS alone (Supplementary Figure S6). 
Only samples treated with a mixture of lipopolysaccharide and 
pIC upregulated these activation markers. Similarly, when we 
monitored cytokine secretion into the media by DCs incubated 
with aptamer:OVA, IFN-γ, IL-6, IL-10, IL-12, macrophage che-
moattractant protein 1, and tumor necrosis factor-α, all remained 
at background levels (Supplementary Figure S7).
Multivalent aptamer conjugates are required for efficient 
in vivo targeting. Systemic injection of DEC205-specific an-
tibodies results in uptake by splenic DEC205+CD11c+CD8α+ 
DCs.23 We therefore used a similar approach to assess the ability 
of our min.2 aptamer to target this cell subset in vivo. Using a bio-
tinylated variant of min.2 or cntrl.36, we generated aptamer:SA-
AF647 conjugates and injected ~20 µg of each construct into mice. 
Interestingly, when conjugates were generated at a 1:1 aptamer to 
SA ratio, conjugate uptake was not detectable (data not shown). 
However, when we saturated SA (a tetrameric protein) with 
four aptamers, uptake of the multivalent aptamer-conjugates by 
splenic DEC205+CD11c+CD8α+ DCs was observed (Figure  4a). 
Importantly, no uptake was seen when similar experiments were 
performed using a nontargeted aptamer control, ctrl.36.
To better assess the role of valency on binding and uptake, we 
performed follow-up experiments in vitro using CHO-DEC205 
cells. Dye-labeled aptamers or aptamer-SA conjugates generated at 
a 1:1 or 4:1 aptamer:SA tetramer ratio were incubated at increasing 
concentrations with CHO-DEC205 cells for 1 hour, after which 
the cells were washed, and the level of cell staining was deter-
mined by flow cytometry. The multivalent conjugates displayed 
an approximately threefold lower apparent binding constant (8.0 
nmol/l) when compared to the aptamer alone or the 1:1 aptamer-
SA conjugate (21.5 and 22.7 nmol/l; Supplementary Figure S8). 
Gel analysis of these SA conjugates suggested that while the 1:1 
conjugates were populated by a mixture of species bearing 0, 1, 
and 2 aptamers per SA (consistent with a Poisson distribution), 
at a 4:1 ratio, the population was dominated by a mixture of spe-
cies bearing mostly 3 and 4 aptamers per protein (Supplementary 
Figure S9). Similar results were observed when experiments were 
performed on A20 cells (data not shown) or when experiments 
were performed using a multivalent min.2:OVA conjugate labeled 
with BOD1PY-FL (Kd app = 15 nmol/l; Supplementary Figure S11).
Multivalent min.2:OVA conjugates are functional for 
crosspresentation in vivo. Consistent with our in vivo targeting 
results, injection of 20 µg monovalent min.2:OVA (conjugated 
at a 1:1 aptamer:OVA ratio) failed to elicit T cell proliferation 
(data not shown). Drawing from our successful targeting experi-
ments (Figure 4a), we reengineered our aptamer-OVA conju-
gates utilizing the longer heterobifunctional linker SM(PEG)12 
which allowed for the addition of multiple aptamers to each 
OVA molecule (>4 aptamers per OVA; Supplementary Figure 
S10). Using this approach, we synthesized and tested conjugates 
bearing 3–4 aptamers per molecule of OVA. The multivalent 
conjugates retained the ability to bind DEC205+ cells with an ap-
parent Kd of ~15 nmol/l (Supplementary Figure S11), but were 
less effective at activating OT-I cells: a ~10-fold higher concen-
tration was needed to achieve similar levels of activation when 
compared to the monovalent conjugates generated with suc-
cinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate  
(Supplementary Figure S12).
As an additional set of controls, we also generated and tested 
OVA conjugates of two mutants of min.2 which largely main-
tained the sequence composition of the parent aptamer but dis-
rupted the predicted folded structure or the order of nucleotides 
in the conserved heptamer (Supplementary Figure S13). Prior 
to conjugation to OVA for in vivo experiments, we used biotinyl-
ated variants of these additional control aptamers complexed with 
AF647-labeled SA at a ratio of 4:1 to assess the relative binding 
affinities of these molecules on CHO-DEC205 cells. As expected, 
the highest amount of aptamer uptake occurred following incu-
bation with multimerized min.2, with lower levels of uptake (9-, 
15-, and 100-fold) observed for the mutants mut.1, mut.2 and the 
control, cntrl.36, respectively (Supplementary Figure S13).
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Using multivalent OVA conjugates bearing either min.2, 
cntrl.36 or mutant aptamers mut.1 and mut.2, at an aver-
age ratio of 3 aptamers per molecule of OVA, we performed 
in vivo activation experiments in C57BL/6 mice injected with 
CFSE-labeled OT-I cells. Min.2 targeting elicited approxi-
mately two- to sixfold more OT-I proliferation when compared 
with cntrl.36:OVA or other control treatments (Figure 4b and 
Supplementary Figure S14). Cytokine production was highest 
in animals that received min.2:OVA and was similar to the level 
observed following treatment with NLDC145:OVA (Figure 
4c,d). We note that injection with ctrl.36:OVA, mut.1, and mut.2 
resulted in some proliferation and cytokine production by OT-I 
cells. However, the overall level of activation was less than that 
observed following min.2:OVA injection, and similar to the 
responses observed following min.2 injection in the absence of 
adjuvant (Figure 4b–d; min.2 (no adjuvant)). Furthermore, as 
observed with our in vitro experiments (Figure 3), min.2:OVA 
must be present as a conjugate to elicit activity—when min.2 
was admixed with OVA and coinjected (min.2+OVA), mini-
mal OT-I activation was observed. Other control treatments 
(pIC alone, Hank's balanced salt solution (HBSS), no injection 
or OVA alone) did not stimulate responses over background 
(Supplementary Figure S14 and data not shown).
Finally, to further demonstrate the functionality of the 
min.2:OVA conjugates, we assessed their ability to activate T cells 
and induce tumor regression using a B16-flank tumor model. 
Mice were given B16 cells expressing OVA (M05) on one flank, 
and palpable tumors developed after 5 days. On day 4, post-tumor 
injection, OT-I cells were transferred into mice and 1 day later 
mice were injected with multivalent aptamer:OVA (min.2 or 
cntrl.36) or NLDC145:OVA plus pIC. As seen in Figure 5, M05 
tumor growth was observed in mice that were untreated (OT-I 
only) or injected with cntrl.36:OVA conjugate. Initial tumor 
growth was observed in mice given either min.2 aptamer:OVA 
or NLDC145:OVA. However, for both of these treatment groups, 
retardation of M05 tumor growth was evident by day 9 (4 days 
postaptamer/antibody injection), and inhibition of tumor growth 
was observed through day 15. At this time point, the experiment 
was terminated due to the large size of the tumors in the control 
groups. B16-OVA tumors in mice that received cntrl.36:OVA were 
significantly larger when compared with those in mice injected 
with min.2:OVA (P < 0.02) or NLDC145:OVA (P < 0.05; analysis 
by two-way analysis of variance). When similar experiments were 
performed on mice given parental B16 tumors (no OVA) on one 
flank, tumor growth was rapid, and progressed with comparable 
kinetics across all treatment groups (data not shown).
Figure 4 Injection of multivalent min.2 results in uptake by DEC205+ dendritic cells that is functional for antigen crosspresentation. (a) Uptake 
of multivalent aptamer-SA conjugates by splenic dendritic cells (DCs). C57BL/6 mice were injected with 20 μg fluorescently labeled multimerized 
cntrl.36, min.2 or NLDC145 antibody. Twenty-four hours later, spleens were harvested, and aptamer uptake by CD11c+DEC205+ cells was determined 
by flow cytometry. The percentage of CD11c+DEC205+ cells that have taken up fluorescent aptamer/antibody is reported in each plot. (b) Activation 
of adoptively transferred OT-I cells following treatment with multivalent aptamer:OVA conjugates. 106 OT-I cells were labeled with carboxyfluorescein 
succinimidyl ester and transferred into congenic B6.SJL-ptprc mice. Twenty-four hours later, mice were injected with 20 μg of aptamer:OVA plus 25 
μg pIC. Three days later, OT-I cell proliferation was determined by flow cytometry. The percentage of TCR-β+CD45.2+ cells present in the total splenic 
population (OT-I cells) is reported on each plot. (c, d) OT-I cells in (b) were analyzed for intracellular expression of interferon (IFN)-γ (c) and interleu-
kin (IL)-2 (d). The percentage of OT-I cells that have undergone three or more divisions is reported in each dot plot. Data shown are representative 
of three experiments. OVA, ovalbumin.
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DISCUSSION
Strategies to target DCs and enhance or control the presentation 
of antigens by these cells are already finding their way into clini-
cal trials.16,24 Of particular interest are approaches in which anti-
gens are specifically directed to bind DC cell surface receptors 
using targeting agents. Receptors such as DEC205, the mannose 
receptor, CD207, DC-SIGN, Clec9a, DCIR2, and others have 
been shown to be good molecular targets for directing cargoes to 
intracellular pathways, which can lead to enhanced antigen pre-
sentation.22–26 Interestingly, different receptors differ in their abil-
ity to stimulate cellular or humoral immunity. This is likely due 
to factors including cellular expression patterns of the various 
receptors and to their relative ability to deliver antigenic cargoes 
to MHC I and II following internalization. For example, in mice, 
delivery of antigen via the DCIR2 receptor promotes antigen 
presentation on MHC II, whereas targeting the DEC205 recep-
tor favors MHC I presentation.22 Moreover, costimulatory signals 
can be used to affect downstream T cell responses. For example, 
codelivery of adjuvants such as pIC or anti-CD40 antibodies 
with antigens conjugated to DEC205-specific antibody leads to 
DC maturation and the production of sustained CD8+ T cell 
responses.5,23 However, in the absence of such additional signals, 
CD8+ proliferation is followed by deletion, leading to tolerance.6 
Thus, these targeted approaches offer the potential to finely tune 
the immunological outcome.
Aptamers that are specific for surface receptors have previ-
ously been used for targeted delivery of molecular cargoes, includ-
ing small molecule drugs,27 toxins and other proteins,28,29 as well 
as nanoparticles.30 And while aptamers have been developed to 
target some immunologically relevant receptors and modulate 
immune responses,9,31,32 aptamers have not yet been used for tar-
geted delivery of antigens.
To test the potential to utilize aptamers in this capacity, we 
generated nuclease-stabilized aptamers that targeted mDEC205. 
Aptamers were generated using a modification of the traditional 
SELEX procedure, which combines recombinant protein with 
a “functional” selection on cells—a strategy we have previously 
employed for the selection of aptamers which target the human 
transferrin receptor.33 DEC-specific activity was apparent in the 
selected population after only three rounds of selection. This was 
likely due to the sensitivity of flow cytometry when compared to 
more traditional metrics for monitoring aptamer library function, 
such as filter binding, which rely on a significant fraction of the 
population binding to the target to yield a positive signal. While 
the function of DEC205 remains unknown, it has been reported 
to be a receptor for apoptotic and necrotic cells34 and phosphoro-
thioated oligonucleotides35 suggesting that DEC205 may simply 
be a “good” SELEX target.
Using a minimized variant, min.2, which is readily amenable 
to chemical synthesis, we generated aptamer:OVA conjugates and 
assessed their ability to specially target CD11C+DEC205+ DCs 
and enhance crosspresentation to CD8+ OT-I T cells in vitro and 
in vivo.
In vitro, in the presence of adjuvant, min.2:OVA was efficient 
at eliciting T cell activation at concentrations as low as 1 nmol/l, 
with no detectable activation observed when similar experiments 
were performed with a nontargeting oligonucleotide control 
(ctrl.36:OVA). T cell proliferation was accompanied by cytokine 
secretion (IL-2, IFN-γ) as determined by intracellular staining for 
flow cytometry and enzyme-linked immunosorbent assay. It is inter-
esting to compare our in vitro aptamer-targeted results with those of 
the anti-DEC205 antibody, NLDC145. In dose–response assays, the 
antibody performed at least 10-fold better than the aptamer showing 
almost complete activation of the T cell population at 100 pmol/l. 
This fact is perhaps not too surprising considering that the observed 
binding constant of our monovalent aptamer is ~20 nmol/l, and 
thus appreciable aptamer binding and subsequent uptake would not 
be expected at concentrations much lower than what we observed. 
While the binding affinity of NLDC145 has not been reported, com-
parable antibodies that target human DEC205 have reported disso-
ciation constants of 100 pmol/l to 1 nmol/l, 10–100-fold lower than 
our aptamer.15 It is also interesting to note that although intracellular 
staining for flow cytometry experiments showed similar levels of 
IL-2 or IFN-γ production for aptamer and antibody-mediated deliv-
ery (Figure 3b–d), analysis of the culture supernatants by enzyme-
linked immunosorbent assay revealed much lower levels of IL-2 
for DCs incubated with min2:OVA conjugates (Figure 3e,f). This 
apparent discrepancy was not due to differences in cell health, as cell 
viability was similar between aptamer- and antibody-treated sam-
ples (data not shown). Altered magnitude or kinetics of IL-2 secre-
tion may be due to differences in potency of T cells in response to 
antibody- versus aptamer-mediated antigen uptake and/or presenta-
tion. IL-2 was detected, albeit at reduced levels, 24 hours following 
OT-I incubation with DCs cultured with min.2:OVA. IL-2 is utilized 
as a T cell growth factor, and the lower levels of IL-2 detected in the 
culture supernatants, when compared with intracellular staining for 
flow cytometry, coincide with T cell expression of IL-2 receptor.36
Our initial attempts to use min2:OVA conjugates to 
prime T cell responses in vivo failed to yield positive results 
Figure 5 Injection of min.2 inhibits growth of established M05 flank 
tumors. Mice were injected s.c. with 106 M05 cells in one flank. Four 
days later, mice received 106 OT-I cells, and the following day mice 
were injected with 10 μg aptamer:OVA (min.2 or cntrl.36) or 5 μg 
NLDC145:OVA plus 25 μg pIC. Tumor growth was monitored and tumor 
area ± SEM is shown. Statistical significance calculated using two-way 
analysis of variance. Comparison of cntrl.36:OVA versus min.2:OVA, P < 
0.02 (*) and cntrl.36:OVA versus NLDC145:OVA, P < 0.05 (*). Treatment 
groups were min.2:OVA (green), ctrl.36:OVA (black), NLDC145:OVA 
(blue), and no treatment (red). Each group contained 5 mice. Data 
shown are representative of two separate experiments. OVA, ovalbumin.
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(data not  shown). This prompted us to assess the localization of 
our aptamers following systemic injection. Interestingly, although 
our min.2 aptamer showed robust cell staining in vitro (Figures 
1e and 2 and Supplementary Figures S1–S4), when the same 
dye-labeled aptamers were injected i.v., subsequent ex vivo anal-
ysis of DEC205+CD11c+CD8α+ DCs by flow cytometry failed to 
demonstrate appreciable cell staining (data not shown). Because 
of their small size, aptamers are rapidly cleared from circulation 
following injection with a t½ = ~10 minutes.37 Additionally, when 
compared to an antibody which bears multiple fluorophores (typi-
cally 3–4 per Ab), aptamers which bear a single fluorophore yield 
a corresponding lower signal. To this end, we utilized a biotinyl-
ated aptamer to generate aptamer-SA conjugates labeled with three 
fluorescent dyes (AF647) to increase both size and brightness. At 
a ratio of 1 aptamer to 1 SA tetramer, this conjugate more closely 
mimics the size of our aptamer:OVA conjugate (75 kDa for the SA 
conjugate and 60 kDa for the OVA conjugates). Interestingly, while 
in vivo uptake of conjugates generated at a 1:1 aptamer to protein 
ratio by splenic DEC205+CD11c+CD8α+ DCs remained undetect-
able, multivalent aptamer constructs assembled using a ratio of 4 
aptamers to 1 SA tetramer stained cells at a similar level observed 
for an antibody (NLDC145) control (Figure 4a), although aptamer 
staining required 10-fold more material than antibody staining 
suggesting that the in vivo targeting by the aptamer conjugates is 
less efficient than that for the antibody when delivered i.v. Using 
an in vitro assay, we assessed the effect of valency on conjugate 
binding and uptake by flow cytometry. Multivalent conjugates dis-
played apparent binding constants approximately two- to threefold 
lower than monomeric conjugates or aptamer only (Figure 1d; 
Supplementary Figures S8 and S11). Thus, while this increased 
affinity may account in part for the observed in vivo efficacy, it 
seems likely that the observed results are due to multiple effects 
including affinity, clearance time and as yet unknown interactions.
In light of the apparent requirement for multivalency, we devel-
oped an alternate approach to generate multivalent aptamer:OVA 
conjugates. Initial attempts using the heterobifunctional cross-
linker GMBS failed to efficiently yield conjugates bearing much 
more than a single aptamer (data not shown). On the other hand, 
using the longer linker SM(PEG)12, we found that as many as 4 
aptamers could be readily appended to OVA following activation. 
Using this approach, we generated aptamer:OVA conjugates at a 
3:1 aptamer:OVA ratio, which resulted in the generation of con-
jugates with ~3–4 aptamers per OVA as determined by sodium 
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) 
analysis (Supplementary Figure S10). Although binding of mul-
tivalent aptamer conjugates in vitro was enhanced when com-
pared with the monovalent conjugates (Supplementary Figures 
S8 and S11), our multivalent OVA conjugates were less effective at 
antigen presentation (Supplementary Figure S12). Why aptamer 
multimerization negatively impacted crosspresentation is not 
known but may be the result of alterations in intracellular traffick-
ing following uptake or simply due to the higher degree of surface 
modification of OVA rendering it more difficult for the cell to pro-
cess. Regardless, subsequent in vivo experiments performed using 
multivalent min.2:OVA conjugates in the presence of adjuvant 
resulted in OT-I activation as determined by CFSE dilution and 
cytokine production (Figure 4 and Supplementary Figure S14). 
Importantly, control experiments performed using a nontarget-
ing control conjugate (cntrl.36:OVA) or two different mutants of 
min.2 (mut.1 and mut.2) that show diminished binding capac-
ity failed to lead to significant T cell proliferation (Figure 4b–d). 
A lack of response was similarly observed with mice that were 
treated with min.2 admixed with OVA, confirming the necessity 
for the aptamer and cargo to be physically linked.
Steinman and coworkers have previously demonstrated that 
OVA delivery using the anti-DEC205 antibody NLDC145 still 
resulted in T cell proliferation in the absence of an added adju-
vant. However, proliferation was not accompanied by activation—
T cells did not produce cytokines and were eventually deleted.6 
Interestingly, when we performed experiments using min2:OVA 
in the absence of the adjuvant pIC, very little proliferation above 
the nontargeted controls was observed suggesting a potential dif-
ference in the pathway or the potency of the immune response 
when antigen is delivered using the min.2 aptamer versus an 
NLDC145 antibody (Figure 4b).
Finally, using a M05 flank tumor model, we found that growth of 
established tumors was slowed following injection of min.2-OVA or 
NLDC145:OVA plus pIC (Figure 5). This OT-I-mediated response 
indicated that injection of min.2:OVA resulted in antigen crosspre-
sentation sufficient to elicit tumoricidal CD8+ T cells. The response 
is equivalent to that observed following treatment with equivalent 
amounts of NLDC145:OVA. Interestingly, both our in vitro and in 
vivo data showed that treatment with NLDC145:OVA results in 
increased proliferation of OT-I cells and higher levels of IL-2 and 
IFN-γ when compared with min.2:OVA. While min.2:OVA injec-
tion elicited reduced proliferation and production of these cyto-
kines, these responses were sufficient to stimulate OT-I cells that 
were functionally competent for inhibiting tumor growth, similarly 
to mice given NLDC145:OVA. Therefore, it seems that the quality 
of the T cell response required for controlling tumor growth was 
comparable, although a more thorough immunological analysis 
will be necessary to substantiate this observation. We also note that 
although our nontargeted control conjugate ctrl36:OVA elicited 
some OT-I activation (Figures 4 and 5), these responses were not 
sufficient to inhibit tumor growth. These data suggest that other, as 
yet unidentified, aspects of T cell function differ significantly when 
comparing min.2:OVA and ctrl36:OVA in vivo responses.
In summary, our work demonstrates a new approach for tar-
geting antigens to specific DC receptors using nucleic acid aptam-
ers. Our min.2 aptamer targets mDEC205+ cells and is functional 
for delivering antigenic cargo for crosspriming in vitro and in vivo. 
We have demonstrated the potential application of this molecule 
for enhancing T cell-mediated immunity as an antitumor ther-
apy. This DC-targeted aptamer could also be developed as a vac-
cine platform, or conversely for ameliorating T cell responses by 
inducing tolerance for treating autoimmunity. When one consid-
ers the potential advantages of aptamer technology over protein 
(antibody) production, aptamers should prove to be a novel pow-
erful tool for use in the clinic.
MATERIALS AND METHODS
Mice. C57BL/6 and OT-I mice were purchased from Taconic (Hudson, NY). 
OT-I mice were on a RAG1−/− background. B6.SJL-Ptprc were purchased 
from Jackson Laboratories (Bar Harbor, ME). All mice used were 6–12 
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weeks old. All experiments were performed in accordance with Institutional 
Animal Care and Use Committee regulations and protocols were approved 
by the Einstein Institutional Animal Care and Use Committee.
Protein expression and purification. CHO cells were cultured in 
Dulbecco’s modified Eagle medium (Life Technologies, Carlsbad, CA) 
supplemented with 5–10% fetal bovine serum (FBS) or 5% Ultra-Low IgG 
FBS supplemented with antibiotic-antimycotic, and nonessential amino 
acids (all from Life Technologies).
CHO cells stably expressing an open reading frame for the full-
length mouse DEC205 (CHO/mDEC205) were generated as previously 
described.15 Similarly, the extracellular domain (residues 1–1,667) of 
mDEC205 was fused in-frame with the hIgG1 FC domain. The mDEC205/
hIgG1FC construct was inserted into the pCMV expression vector 
(Clontech, Mountain View, CA) and transfected into CHO cells to generate 
stably expressing CHO/mDEC205/hIgG1FC cells. Culture supernatant 
from these cells was used to purify the mDEC205/hIgG1FC fusion protein 
by affinity to Protein A Sepharose (GE Healthcare, Pittsburgh, PA).
Aptamer selection. The sequence of the N50 library used for selection 
against mDEC205 was: 5′GGGAGGTGAATGGTTCTACGAT-N50-
TTACATGCGAGATGACCACGTAATTGAATTAAATGCCCGCCATG
ACCAG-3′. The single-stranded DNA library was synthesized such that N 
regions contained an equal probability of containing A, T, G, or C, as pre-
viously described.38 Following deprotection, the library was gel purified by 
denaturing (7 mol/l urea) gel electrophoresis on an 8% polyacrylamide gel. 
The single-stranded DNA library was amplified by polymerase chain reac-
tion (PCR) to generate a double-stranded DNA bearing a T7 promoter and 
transcribed in vitro using the Y639F mutant of T7 RNA polymerase39,40 and 
2′-fluoro (2′-F) pyrimidines. Following transcription, the RNA was puri-
fied on a denaturing (7 mol/l urea) 8% polyacrylamide gel.
For Round 1, we utilized ~3 copies of an RNA library encompassing 
~1 × 1014 sequences (~20 µg). The library was diluted in 20 µl HBSS (Life 
Technologies) and then thermally equilibrated by incubation at 70 °C for 
5 minutes, followed by room temperature for 15 minutes prior to addition 
to the immobilized protein target (mDEC205/hIgG1FC).
Immobilized protein was prepared by incubating 25 pmol mDEC205/
hIgG1FC with 25 μl of washed Dynabeads Magnetic Protein G resin in 200 μl 
of washing/blocking buffer (0.1 mol/l NaPO4 pH 8.2, 0.01% Tween 20). 
This mixture was incubated 30 minutes at room temperature with rotation 
and then washed three times with 200 μl DPBS without Ca2+ or Mg2+ (Life 
Technologies). After the third wash, buffer was removed and replaced with 
the RNA library in a final volume of 20 µl. The resin was then incubated 
for an additional 30 minutes at room temperature with rotation, followed 
by three washes with 200 μl HBSS. After the third wash, protein and RNA 
were eluted by a 5-minute incubation with 20 μl 200 mmol/l glycine, pH 
2.5. The eluent was combined with 400 μl 0.3 mol/l NaOAc, containing 4 μg 
glycogen and the RNA recovered by ethanol precipitation.
The recovered RNA was reverse transcribed to single-stranded DNA 
(ssDNA) using Moloney murine leukemia virus reverse transcriptase 
(M-MLV RT, Life Technologies). The ssDNA was amplified by PCR using 
Taq DNA polymerase, and PCR product was transcribed into 2′-F-Y-RNA 
by a modified T7 RNA polymerase (Y639F39 and P266L41 mutations). For 
subsequent rounds, 1 μg of the previous round’s selection product was 
prepared as above for Round 1.
Prior to Rounds 2 and 3, we used a negative selection step to deplete 
resin-binding aptamers and aptamers that bound the FC region from the 
population. The negative selection step was performed by incubating 
the library with 20 μl Dynabeads Protein G resin prepared as above, but 
substituting 50 pmol human IgG1 FC region (hIgG1FC) for mDEC205/
hIgG1FC fusion protein. Protein G resin loaded with hIgG1FC was then 
incubated with the prepared RNA for 30 minutes at room temperature 
with rotation, after which the resin was spun down, and the supernatant 
was removed and added to 20 μl Dynabeads Protein G resin loaded with 
25 pmol mDEC205/hIgG1FC, as above. RNA was recovered, reverse 
transcribed, amplified, and transcribed as described above.
Round 4 was performed using CHO-mDEC205. Prior to the positive 
selection, we performed a negative selection on the parental CHO cells. 
In short, 5 μg of RNA was combined with a twofold molar excess of 
reverse primer used for amplification (T50R). The mixture was diluted 
to a final volume of 50 μl in HBSS, denatured for 5 minutes at 70 °C, 
and allowed to anneal for 15 minutes at room temperature. Reannealed 
RNA was added to ~1 × 105 CHO cells in a 24-well plate containing 450 
μl media and incubated for 30 minutes at 37 °C. Following incubation, 
the media (containing nonbound RNA) was removed from the CHO cells 
and transferred to a well containing ~1 × 105 CHO/mDEC205 cells. The 
RNA was incubated with CHO/mDEC205 for 1 hour at 37 °C, after which 
cells were washed three times with 1 ml HBSS, and cells were lysed for 5 
minutes at room temperature with 500 μl TRIzol. Recovered RNA was 
reverse transcribed, amplified, and transcribed as described above.
For Round 5, we performed an “internalization selection” in which 
we targeted BMDCs. BMDCs were prepared from mouse bone marrow 
by treatment for 5 days with granulocyte-macrophage colony-stimulating 
factor (GM-CSF) as previously described.17 RNA (5 μg) was combined with 
a twofold molar excess of reverse primer used for amplification (T50R). The 
mixture was diluted to a final volume of 50 μl in HBSS, denatured for 5 
minutes at 70 °C, and allowed to anneal for 15 minutes at room temperature. 
The RNA was subsequently added to one well of a 24-well plate containing 
~5 × 104 BMDCs in 450 μl advanced Roswell Park Memorial Institute 
medium (RPMI) 1640 containing 10% FBS and 5% J5 medium (supernatant 
from J558 cells transfected to express GM-CSF supplemented with single-
stranded DNA and transfer RNA (1 mg/ml each).
After a 1-hour incubation at 37 °C, the media was removed, and cells 
were washed three times with 1 ml HBSS containing 0.1% NaN3 followed 
by a single wash with 1 ml cold 200 mmol/l glycine, 150 mmol/l NaCl, 
pH 4. The cells were subsequently washed an additional three times with 
1 ml HBSS containing 0.1% NaN3 followed by 1 ml DPBS without Ca
2+ or 
Mg2+ and trypsinized by the addition of 500 μl 0.05% trypsin, 0.53 mmol/l 
ethylenediaminetetraacetic acid for 15 minutes at 37 °C. Following an 
additional wash with 1 ml HBSS containing 0.1% NaN3, the cells were 
pelleted and resuspended in 100 μl HBSS containing 5 μl RiboShredder 
ribonuclease cocktail (EpiCentre, Madison, WI). The reaction was 
incubated for 15 minutes at room temperature, after which the cells were 
washed three times with 1 ml HBSS + 0.1% NaN3 and lysed for 5 minutes 
at room temperature with 500 μl TRIzol. RNA was recovered, reverse 
transcribed, amplified, and transcribed as described above.
PCR product from Round 5 was cloned into the pCR2.1-TOPO TA 
vector by TOPO TA cloning (Life Technologies).
Chemical synthesis of RNA aptamers. Minimized aptamers and con-
trols were synthesized in our laboratory on an Expedite 8909 DNA 
synthesizer (Applied Biosystems, Carlsbad, CA) using 2′-fluoro-deox-
ycytidine and 2′-fluoro-deoxyuridine phosphoramidites (Metkinin, 
Kuusisto, Finland). Unless noted otherwise, all other synthesis reagents 
were purchased from Glen Research (Sterling, VA). The aptamer was 
synthesized bearing a 5′ thiol modification using a thiol-modifier C6 
S-S phosphoramidite and a 3′ inverted dT residue for added serum sta-
bility. The sequences of the minimized aptamer, min.2, and a nonbind-
ing control aptamer, c36, an aptamer-like, nonfunctional sequence 
which we have previously utilized as a nonbinding control6 were: 5S 
GGGAGGUGUGUUAGCACACGAUUCAUAAUCAGCUACCCUCCCt 
and 5SGGCGUAGUGAUUAUGAAUCGUGUGCUAAUACACGCCt, 
respectively, where “t” is a 3′ inverted dT and “5S” is the 5′ thiol. All aptam-
ers were synthesized with the final 4,4′-dimethoxytrityl protecting group 
left on. Following deprotection, aptamers were purified by reversed-phase 
high-performance liquid chromatography on a 10 × 50 mm Xbridge C18 
column (Waters, Milford, MA) using a linear gradient of acetonitrile in 
0.1 mol/l triethylammonium acetate at pH 7.0.
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Aptamer binding by flow cytometry. Aptamer binding was assessed by 
flow cytometry. Rounds from the selection were first hybridized to a bio-
tinylated labeled oligonucleotide that was complementary to the 3′ end of 
the library (T50R). In a typical assay, 10 pmol of transcribed RNA pool 
was added to 11 pmol biotinylated T50R (B-T50R) in 10 μl of DPBS. The 
RNA was thermally equilibrated by heating to 70 °C for 3 minutes and 
then allowed to cool on the bench for 15 minutes at room temperature. 
The RNA was subsequently added to 1 × 105 cells in 100 μl flow cytom-
etry buffer (HBSS containing 1% BSA and 0.1% NaN3) supplemented with 
1 mg/ml ssDNA. The RNA and cells were incubated for 15 minutes on ice, 
pelleted by centrifugation, washed once with 1 ml flow cytometry buffer 
and then resuspended in 100 μl flow cytometry buffer containing 0.5 μl 
PhycoLink SA-R-PE (SA-PE), and incubated an additional 15 minutes 
on ice. Cells were then washed with an additional 1 ml flow cytometry 
buffer, resuspended with 500 μl flow cytometry buffer, and analyzed by 
flow cytometry, with exclusion of dead cells by 7-aminoactinomycin D 
(7-AAD) or 4′,6-diamidino-2-phenylindole (DAPI) staining.
Flow cytometry: fluorophore or biotin-conjugated aptamers. Thiolated 
aptamers (5S.min2 or 5S.cntrl36) were used to generate the Alexa Fluor 
488 (AF488), Dylight 647 (Dy647), or biotin-labeled aptamers used for 
flow cytometry. Labeling was performed using AF488-C5-malemide (Life 
Technologies), Dylight 647 maleimide (Pierce, Rockford, IL), or bio-
tin maleimide (Pierce) as follows: thiolated aptamer was reduced using 
10 mmol/l tris(2-carboxyethyl)phosphine (TCEP) in 100 μl of 0.1 mol/l 
triethylammonium acetate. Samples were heated at 70 °C for 3 minutes 
followed by incubation at room temperature for 1 hour. The reduced 
aptamers were desalted using a Biospin 6 column (BioRad, Hercules, 
CA) into phosphate-buffered saline (PBS) supplemented with 50 mmol/l 
phosphate pH 7.5. Typically, the maleimide in dimethyl sulfoxide was 
added at a 3–10-fold molar excess over ~10 nmoles of aptamer in 100 μl 
of 50 mmol/l phosphate, pH 7.5. Following an overnight reaction at 4 °C, 
the aptamer was desalted an additional time using a Biospin 6 column. 
Conjugations proceeded to >99% as determined by high-performance 
liquid chromatography with complete removal of free dye or biotin.
In a typical cytometry assay, 100 pmol of dye/biotin-conjugated 
RNA was diluted into 100 μl DPBS, denatured for 3 minutes at 70 °C and 
allowed to cool for 15 minutes at room temperature. Cell staining was 
performed as described.
Aptamer binding and internalization experiments were performed 
using BMDCs and CHO-DEC205 cells. To generate BMDCs, bone 
marrow from the femur and tibia was cultured for 8 days in RPMI 
complete media plus GM-CSF (10 ng/ml) and MACS sorted for CD11c+ 
cells (Miltenyi Biotec, San Diego, CA)17 prior to use. For each experiment, 
106 cells were resuspended in RPMI complete media containing blocking 
reagents (tRNA and ssDNA at 1 mg/ml). Biotinylated min.2 or cntrl.36 
were thermally equilibrated and mixed at a 1:1 with SA-PE for 15 minutes 
prior to addition to cells and allowed to incubate for 30 minutes at 4 °C. 
To determine binding, cells were washed twice and treated with or without 
Riboshredder for 10 minutess at 37 °C to digest any cell-surface bound 
aptamer:PE. To determine internalization, following incubation at 4 °C, 
cells were moved to 37 °C for 1 hour. The cells were then washed twice and 
incubated with or without Riboshredder for 10 minutes at 37 °C. Cells were 
then washed and stained with Fc block (anti-mouse CD16; eBioscience, 
San Diego, CA) and CD11c-APC for 30 minutes at 4 °C. Cells were washed 
twice, stained with the viability dye DAPI, and analyzed by flow cytometry.
mDEC205 cell surface binding assays and the determination of appar-
ent binding constant. A20.Kb cells were washed with RPMI and resus-
pended at 1 × 106 cells per milliliter in RPMI supplemented with 1 mg/
ml ssDNA. 100 µl cells were incubated with increasing concentrations of 
thermally equilibrated Alexa Fluor 488-conjugated min.2 or Alexa Fluor 
488-conjugated cntrl.36 for 15 minutes at 37 °C. Following incubation, 
the cells were washed with and resuspended in flow cytometry buffer, and 
analyzed by flow cytometry. Median Alexa Fluor 488 fluorescence of live 
(DAPI−) cells was plotted versus min.2 or cntrl.36 concentration using 
GraphPad Prism, and the dissociation constant (KD) was calculated by 
fitting a one site binding model to the data.
A20.Kb cells and A20.Kb.mDEC205 cells were generated from A20 
cells by viral transduction. The cell lines were generated by superinfection 
with retroviruses made from pMX-Kb and/or pMX-mDEC205 as 
described previously.42
Synthesis of aptamer OVA conjugates. Thiolated aptamers (5S.min2 or 
5S.cntrl36) were used to generate the aptamer OVA conjugates. Pierce 
Imject OVA was activated with a 10-fold molar excess of N-[γ-maleimid
obutyryloxysulfosuccinimide ester (sulfo-GMBS, Pierce) in 1 mmol/l eth-
ylenediaminetetraacetic acid in DPBS without Ca2+ or Mg2+ according to 
the manufacturer’s protocol, and excess sulfo-GMBS was removed with a 
Micro Bio-Spin 6 column.
Thiolated aptamers were reduced using 10 mmol/l TCEP and 
subsequently desalted using a Bio-Spin 6 column into DPBS without Ca2+ 
or Mg2+. The reduced aptamers were incubated with a fivefold molar excess 
of sulfo-GMBS-activated OVA. The reaction mixture was incubated for 30 
minutes at room temperature or overnight at 4 °C and then quenched 
by incubation with excess L-cysteine or BODIPY FL L-cysteine (Life 
Technologies) that had previously been reduced with TCEP.
The reaction mixture was desalted to 20 mmol/l Tris, pH 7 with a 
Bio-Spin 6 column and then purified on a Mini Q 4.6/50 PE column (GE 
Healthcare) equilibrated with the same buffer, and the eluted fractions 
were analyzed by denaturing gel electrophoresis (Supplementary Figure 
S5). Conjugate function was confirmed by flow cytometry using BODIPY 
FL L-cysteine quenched conjugates (Supplementary Figure S5).
Mulitmeric aptamer conjugates were generated using a similar 
approach. In short, OVA was activated with a 50-fold molar excess of the 
heterobifunctional crosslinker SMPEG12 (Pierce) in place of sulfo-GMBS. 
The reaction was allowed to proceed for 3 hours at room temperature, 
after which excess crosslinker was removed by ultrafiltration using an 
Amicon Ultra, Ultracell 30K filter (Millipore, Billerica, MA). The reduced 
aptamers we incubated at a 3:1 ratio with activated OVA overnight at 4 
°C, after which the reaction was quenched by the addition of 100-fold 
excess of β-mercaptoethanol. Conjugation efficiency routinely proceeded 
to >90% as determined by denaturing (7 mol/l urea) gel electrophoresis 
and SDS–PAGE (Supplementary Figure S8). Multimer:OVA conjugate 
function was confirmed by flow cytometry on CHO-mDEC205 cells 
by replacing β-mercaptoethanol in the quench step with BODIPY FL 
L-cysteine (Life Technologies) that had previously been reduced with 
TCEP (Supplementary Figure S11).
Confocal microscopy. 2 × 105 CD11c+ BMDCs or CHO-DEC205 cells 
were plated onto poly-L-lysine coated circular glass coverslips in complete 
media. CD11c+ BMDCs were treated in 500 µl RPMI complete medium 
containing 10 ng/ml GM-CSF. CHO-DEC205 cells were treated in 500 µl 
complete Dulbecco’s modified Eagle medium. To visualize aptamer-Dy649 
binding, plates were moved to 4 °C and incubated with 200 nmol/l aptamer-
Dy649 in presence of blocking agents (1 mg/ml ssDNA and tRNA) for 60 
minutes. Cells were then moved to 37 °C for 2 hours to allow for aptamer 
internalization. Cells were then washed with complete medium to remove 
unbound aptamer, followed by staining with Fc block and either 10 µg/ml 
DEC205-biotin (CHO-DEC205) or CD11c-biotin (CD11c+ BMDCs) for 
30 minutes at 4 °C. Cells were then washed twice with complete medium 
and stained with SA-Alexa488 (10 µg/ml) for 30 minutes at 4 °C. Cells 
were washed twice with cold PBS, fixed with 2% paraformaldehyde, fol-
lowed by three washes with cold PBS. Coverslips were mounted with 20 
µl Vectashield mounting medium containing DAPI. Images were acquired 
on a Leica SP5 AOBS instrument using the 40x oil immersion objective.
For colocalization studies, 15,000 CHO-DEC205 cells (removed 
from  primary flasks using 5 mmol/l ethylenediaminetetraacetic acid in 
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PBS—not trypsin) were plated in 8-well chamber slides in complete media 
(advanced Dulbecco’s modified Eagle medium, 5% FBS, supplements 
2-ME/L-glutamine) and allowed to adhere for 2 hours at 37 °C 5% CO2. 
8-well chamber glass bottom slides (LabTek 15547) were pretreated with 
fibronectin at 25 µg/ml for 30 minutes at room temperature prior to use. 
Experiments involving coincubation of min.2 and DEC205 antibody were 
performed using 250 nmol/l min.2-DyLight 650 and 0.2 µg/ml DEC205-
Alexa Fluor 488 antibody (clone 205yekta; eBioscience). Experiments 
involving early endosome or lysosome colocalization studies were 
performed using CHO-DEC205 cells transduced with a baculovirus vector 
containing mRFP tagged Rab5a or LAMP1 (Cell Light Reagents BacMam 
2.0, Life Technologies). Adherent CHO-DEC205 cells were transduced in 
complete media at 75 particles/cell. Sixteen hours posttransduction, cells 
were incubated with 250 nmol/l min2-Alexa Fluor 488 aptamer or 0.2 µg/
ml DEC205-Alexa Fluor 488 antibody for 2 hours, after which the cells were 
washed with complete media and incubated 1 additional hour. Following 
incubation, cells were washed and then fixed with 4% paraformaldehyde 
for 20 minutes at room temperature. The fixed cells were again washed and 
the cell nuclei stained with DAPI. Samples were visualized using a Leica 
SP5 AOBS confocal microscope using a ×63 oil objective. Captured images 
were converted to the TIFF format using Leica LAS-AF software (Leica 
Microsystems, Buffalo Grove, IL). Image processing was performed using 
NIH ImageJ (National Institutes of Health, Bethesda, MD).
In vitro proliferation assays. A single-cell suspension of splenocytes from 
C57BL/6 mice, aged 6–12 weeks, was prepared using 400 U/ml collagenase 
D (Roche, Indianapolis, IN), and CD11c+ cells were isolated using biotinyl-
ated antibody clone N418 and MACS SA microbeads, or MACS CD11c+ 
microbeads alone, according to the manufacturer’s protocol (Miltenyi 
Biotec). CD11c+ splenic DCs were plated in a 96-well U-bottom plate 
at 4 × 105 in 100 μl Advanced RPMI 1640 (Life Technologies) containing 
10% FBS, Penicillin-Streptomycin (Life Technologies), GlutaMAX-I (Life 
Technologies) and 10 mmol/l hydroxyethyl piperazineethanesulfonic acid 
(MPBio, Santa Ana, CA) (complete culture medium), 1 μg/ml lipopolysac-
charide from Escherichia coli O111:B4 (Sigma-Aldrich, St Louis, MO), and 
10 μg/ml polyinosinic-polycytidylic acid (pIC, Sigma-Aldrich). The cells 
were incubated for 4 hours at 37 °C, after which the media was replaced 
with media of the same formulation containing additional 1 mg/ml ssDNA 
and 10 nmol/l of either Imject OVA, rat IgG2a isotype antibody-OVA chi-
mera (Iso:OVA), NLDC145:OVA chimera (NLDC145:OVA), monovalent 
cntrl.36:OVA, or min.2:OVA (several wells received an equivalent volume 
of DPBS as a negative control). The cells were incubated for an additional 
16–20 hours at 37 °C.
The next day, a single-cell suspension of lymph node cells was prepared 
from the axillary, brachial, inguinal, popliteal, and mesenteric lymph nodes 
of 6–12-week-old C57BL/6 RAG−/− OT-I+/+ (OT-I) mice. The OT-I cells 
were resuspended in DPBS containing 5% FBS, CFSE was added to 5 μmol/l, 
and the cells were incubated for 5 minutes at 37 °C protected from light. The 
reaction was quenched by adding 10 volumes of complete culture medium 
and incubating for 5 minutes at room temperature. Cells were washed three 
times in complete culture medium and resuspended in complete culture 
medium at 1 × 106 cells/ml. After their 16–20-hour incubation, the CD11c+ 
splenocytes were washed three times with DPBS, 1 × 105 CFSE-labeled OT-I 
cells were added, and the cells were incubated an additional 2–3 days at 37 
°C. At the end of this incubation, cells were resuspended, washed with flow 
cytometry buffer, stained with DAPI and antibodies against CD8α and T 
cell receptor (TCR)-β, and analyzed by flow cytometry.
Similar experiments were performed to assess the function of our 
multivalent aptamer:OVA conjugates (Supplementary Figure S12).
In vitro cytokine production. CD11c+ splenic DCs were prepared as 
described above and treated in triplicate with 10 nmol/l of either of the 
following: Imject OVA, SIINFEKL (OVA257–264) peptide, rIgG2a:OVA, 
NLDC145:OVA, cntrl.36:OVA, or min.2:OVA. OT-I cells were prepared 
as described above, except for CFSE staining. After a 16–20-hour incuba-
tion with antigen at 37 °C, the CD11c+ splenic DCs were washed care-
fully three times with DPBS, and 1 × 105 OT-I cells were added. Following 
incubation at 37 °C for 2 additional days, media was removed and saved 
for analysis of secreted IL-2 and IFN-γ by enzyme-linked immunosorbent 
assay. Fresh media containing 10 μg/ml brefeldin A (Life Technologies) 
was added, and cells were incubated for 5 hours at 37 °C. Cells were then 
resuspended and stained for the cell surface molecules CD8α and TCR-β, 
followed by fixation with 4% paraformaldehyde (Sigma-Aldrich) in pH 7 
PBS for 10 minutes at 37 °C. Cells were washed, permeabilized with 0.1% 
saponin (Sigma-Aldrich) in flow cytometry buffer and stained with anti-
bodies against IL-2 and IFN-γ, and analyzed by flow cytometry.
In vivo uptake of aptamer-SA conjugates. Aptamer:SA conjugates were 
synthesized at a ratio of 1:1 and 4:1 (aptamer:SA) using biotinylated 
aptamers (synthesized from thiol modified aptamers as described above) 
and SA-AF647 (Life Technologies) by simple mixing at the appropriate 
ratio. The approximate number of aptamers per protein was determined by 
SDS–PAGE gel electrophoresis. At a mixing ratio of 1:1, conjugates appear 
as a mixture of species bearing 0, 1, and 2 aptamers, whereas at a ratio 
of 4:1, conjugates appear as a mixture of species bearing 3 or 4 aptam-
ers (Supplementary Figure S8). Approximately 20 µg aptamer conjugate 
was injected, i.v. into C57BL/6 mice. One day later, spleens were isolated, 
digested with 400 units collagenase D (Roche), and following red blood 
cell lysis, splenocytes were stained with antibodies specific for CD11c and 
DEC205. Splenocytes were stained with the viability dye Live/Dead Fixable 
Blue (Life Technologies) and were acquired on an LSRII (BD). Analysis 
was performed using FlowJo (Treestar, Ashland, OR).
In vivo crosspresentation with aptamer:OVA conjugates. OT-I lymph 
node cells were labeled with 5 µm CFSE and 106 cells were adoptively trans-
ferred into a congenic recipient (B6.SJL-Ptprc) by retroorbital injection. 
One day later, mice were injected retroorbitally with either 20 µg multiva-
lent aptamer:OVA (min.2, mut.1, mut.2, or ctrl.36) or controls (pIC alone, 
OVA alone, min.2+OVA admixed, HBSS buffer or 1 µg NLDC145:OVA). 
Unless stated, all injections included the adjuvant pIC (25 µg per mouse). 
Three days later, spleens were removed, red blood cells were lysed, and 
5 × 106 splenocytes were incubated for 4 hours in the presence of 5 µg/ml 
brefeldin A with or without 1 µmol/l of the OVA peptide, SIINFEKL. Cells 
were then stained for cell surface markers, TCR-β and CD45.2, followed 
by fixation with 4% paraformaldehyde. Intracellular IL-2 and IFN-γ were 
detected by incubating cells with antibody in the presence of 0.3% saponin. 
Cells were then acquired on an LSRII and analyzed by FlowJo. Dead cells 
were excluded using live/dead viability dye.
B16-OVA flank tumor model. C57BL/6 mice were s.c. injected with 106 
B16-OVA cells (M05). Four days later, 106 OT-I cells isolated from lymph 
nodes were injected into the mice i.v. into the retroorbital sinus. The fol-
lowing day, groups of 5–6 mice were injected i.v. with 10 µg cntrl36:OVA, 
min.2:OVA, or 5 µg NLDC145:OVA plus 25 µg pIC. One group of mice was 
left untreated. Tumor growth was monitored every 2 days until the tumors 
reached 1 cm in diameter, at which time mice were euthanized. Experiments 
were also performed using mice injected with 106 B16-OVA cells (M05) in 
one flank and 5 × 104 parental B16 cells (no OVA) in the opposite flank. 
However, rapid growth of the parental B16 across all treatment groups 
resulted in termination of these experiments prior to observing significant 
inhibition in min.2:OVA and NLDC145:OVA treated groups.
SUPPLEMENTARY MATERIAL
Figure S1. Selection of DEC205-specific aptamers.
Figure S2. Analysis of Clone 1 minimizations 1-5.
Figure S3. Min.2 specifically binds the DEC205 receptor.
Figure S4. Min.2 and NLDC145 bind DEC205+ cells.
Figure S5. Characterization and purification of aptamer:OVA 
conjugates.
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Figure S6. Aptamer:OVA conjugates do not activate CD11c+ splenic 
DCs.
Figure S7. Cytokine analysis of media from CD11c+ splenocytes 
treated as described in Figure S6.
Figure S8. Cytometric analysis of monovalent and multivalent 
aptamer:streptavidin conjugates on CHO-DEC205 cells.
Figure S9. Analysis of the effects of conjugate valency on binding.
Figure S10. Representative analysis of multivalent aptamer:OVA con-
jugates by gel electrophoresis.
Figure S11. Binding analysis of multivalent aptamer:OVA conjugate.
Figure S12. Multivalent min.2:OVA conjugates show diminished 
capacity for antigen presentation in vitro.
Figure S13. Mutant forms of min.2 bind DEC205 with lower affinity 
and are less effective at cross-presentation when compared with min.2.
Figure S14. Activation of adoptively transferred OT-I cells following 
treatment with multivalent aptamer:OVA conjugates.
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